^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ADCT-211

    i
    Other names: ADCT-211
    Company:
    ADC Therapeutics
    Drug class:
    DNA replication inhibitor, IL-13Rα2-targeted antibody-drug conjugate
    Related drugs:
    1year
    Preclinical development of ADCT-211, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting solid tumors expressing IL13RA2 (AACR 2023)
    ADCT-211 is an antibody-drug conjugate composed of HuCl47, a humanized IgG1 antibody directed against human IL13RA2, site-specifically conjugated using GlycoConnectTM technology to PL1801, which contains HydraspaceTM, a valine-alanine cleavable linker and the PBD dimer cytotoxin SG2000 (drug to antibody ratio ~ 1.8). Expression of membranous IL13RA2 was confirmed by IHC in a panel of primary and refractory GBM samples and malignant melanoma, highlighting them as potential indications for the clinical development of ADCT-211. In conclusion, ADCT-211 demonstrated potent and specific in vitro and in vivo anti-tumor activity and it was stable and well tolerated in the rat, warranting further development of ADCT-211 into the clinic in IL13RA2-expressing cancers.
    Preclinical
    |
    IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2) • IL13 (Interleukin 13)
    |
    IL13RA2 expression
    |
    ADCT-211 • SG 2000